Ray Therapeutics, Inc.

Our Chief Development Officer Jenny Holt joined an insightful panel today at LSX World Congress, moderated by Christian Nodgaard (RSM), alongside Scott Saywell (Coherus Oncology) and milenko cicmil (Tasca Therapeutics). We explored one of the most critical transitions for any biotech: moving from R&D into the pre-commercial and commercial phases. A few key takeaways we discussed: 🔹 Commercial planning can’t wait until pivotal trials—you need to start early. 🔹 Scalable CMC and a clear view of patient demand are essential for long-term success. 🔹 Communication and hitting milestones are critical to building trust with investors and key stakeholders. Grateful for the chance to share experiences, learn from peers, and connect with so many innovators driving our industry forward. #LSXWorldCongress #Biotech #GeneTherapy #Optogenetics

Excited to share that our Chief Development Officer, Jenny Holt, will be speaking at LSX World Congress USA in Boston on September 16–17, 2025. Jenny will join an outstanding panel of industry leaders for: “From Molecules to Millions: How to Build a Biotech Powerhouse” 📅 Tuesday, September 16, 2025 | 11:00–11:40 AM ET Alongside peers from Coherus BioSciences, Tasca Therapeutics, Biolinq, and RSM US LLP, Jenny will discuss the strategies and milestones that turn breakthrough science into sustainable biotech businesses. 👉 Learn more about the panel here: https://lnkd.in/exAJtMnz #Biotech #LSXUSA #LifeSciences #Innovation

Peter Francis, MD PhD, Chief Medical & Scientific Office of Ray Therapeutics, Inc. on the origins of Vision Research and Assessment Institute (VRAI). Spun out of Ray, this independent institute is designed to developing and implementing robust methods for assessing visual function in individuals participating in clinical trials. VRAI is a state-of-the-art facility dedicated to ophthalmic efficacy testing, integrating a specialized reading center and advanced functional vision assessments to ensure precise clinical outcomes and support faster drug approvals.

In this podcast from the 2025 Chief Medical Officer Summit 360°, CMOs discuss key strategies for collaborating with regulatory teams and engaging productively with the FDA and other regulatory agencies. Specifically, the panelists address: - Engaging with the FDA on a peer-to-peer level - Effectively negotiating about innovative approaches that may be outside of guidelines - How to react and respond to feedback and questions from the FDA Speakers include: -Peter Francis, Ray Therapeutics, Inc. -Norman Sussman, DURECT Corporation -Harpreet Singh, Precision For Medicine -Richard Scranton, Lyndra Therapeutics Tune in here: https://lnkd.in/eF7CCmWs #CMOSummit360

🌟 From Molecules to Millions: How to Build a Biotech Powerhouse Ready to uncover the secrets to building a biotech powerhouse? Join us for an insightful discussion with industry leaders as we explore how to transform groundbreaking science into commercial success and navigate the challenges of scaling innovation in biotech. Hear from: • Joseph Goldberg, National Life Sciences Industry Consulting Leader, RSM US LLP • Scott Saywell, EVP, Corporate Development, Coherus BioSciences • Paul Bresge, CEO, Ray Therapeutics, Inc. • milenko cicmil, CEO & Co-Founder, Tasca Therapeutics • Rich Yang, CEO, Biolinq 🤝 Join 1000+ innovators, investors, and life science leaders for two days of innovation, investment, and partnering. 📆 September 16-17, 2025 📍 BCEC, Boston, USA 📚 Get the event details: Download the brochure https://lnkd.in/edWQ2eNs #LSXUSA #Biotech #Innovation #Commercialisation #LifeSciences

Our CEO, Paul Bresge, joined an inspiring group of leaders on the "Improving & Restoring Vision in Blinding Eye Diseases," panel at #BIO2025. Joining him on stage was our moderator Jason Menzo, CEO, Foundation Fighting Blindness, and panelists Lance Baldo, Arnaud Lacoste, PhD MBA, Samarendra Mohanty, and Patrick Ritschel, to discuss the next generation of therapies for retinal and corneal diseases. Many blinding eye diseases still have no cure and for some, there hasn’t been meaningful innovation in decades. But we’re now at a tipping point. From gene therapies to regenerative approaches, the field is rapidly evolving, with novel therapies advancing in development. Thanks again to BIO, and to our moderator Jason Menzo for an engaging discussion. #BIO2025 #ophthalmology #genetherapy #retinaldisease #biotech

Gene therapy, optogenetics, and cell-based approaches are transforming what’s possible for patients with both rare and common degenerative retinal diseases. Join Paul Bresge, CEO of Ray Therapeutics, Inc., at #BIO2025 as he speaks on the panel: Panel: Improving and Restoring Vision in Blinding Eye Diseases Date/Time: Tuesday, June 17, 1:45–2:45 PM ET Location: Room 254B, Boston Convention Center This panel will explore: Cutting-edge therapeutic platforms for corneal and retinal disease Strategies for navigating today’s investment and regulatory climate Impacts of recent FDA/NIH budget shifts on innovation and advocacy Paul will be joined by fellow CEOs and R&D leaders from the forefront of vision restoration—including Beacon Therapeutics, Aurion Biotech, Atsena Therapeutics, and Nanoscope Therapeutics Inc.—moderated by Jason Menzo, CEO of the Foundation Fighting Blindness. Ray Therapeutics is developing optogenetic therapies to restore vision in patients with inherited retinal diseases and other forms of blindness. More info about the panel: https://rb.gy/o9cku4 Hope to see you in Boston!

Catch up on this week's top news stories >>> https://bit.ly/4cWVBb2 🗞️Abeona Therapeutics received FDA approval for the first/only cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa 🗞️QIAGEN expanded its dPCR portfolio to support quality control processes for lentivirus-based cell and gene therapies 🗞️Ray Therapeutics, Inc. was awarded a grant of $8 million by California Institute for Regenerative Medicine (CIRM) to support the development of an optogenetic gene therapy for retinitis pigmentosa

We’re excited to announce a $8 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will support the company’s ongoing clinical development of RTx-015 for the treatment of retinitis pigmentosa, a progressive and debilitating inherited retinal disease that leads to blindness. Our gene therapy program received a unanimous vote of support from CIRM’s scientific and patient advocate reviewers. “Retinitis pigmentosa remains a devastating condition with no approved treatments for the vast majority of patients,” said Paul Bresge, CEO & Co-Founder, Ray Therapeutics. “We are deeply grateful to CIRM for their belief in our science and their continued support of our programs. We are honored to partner with CIRM as we advance therapies that have the potential to transform the lives of patients.” Read the release: https://lnkd.in/e8yzz5SY